Rajaraman et al., showed that a sequential triple combination of TMZ or lomustine, oncolytic MV, and radiation therapy had a synergistic antitumor effect in glioma or stem-like glioma cell lines and identified a treatment-induced molecular and immunological signature [136], including an increase in chemokines regulating the immune response, an increase in the antigen presentation machinery, and in PD-L1 transcription. The gene discussed is CD274; the disease is central nervous system cancer.